Andrew Guggenhime - 25 Aug 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
President and CFO
Signature
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
25 Aug 2022
Net transactions value
-$815,400
Form type
4
Filing time
29 Aug 2022, 17:46:10 UTC
Previous filing
22 Aug 2022
Next filing
07 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $91,228 +17,052 +40% $5.35 59,239 25 Aug 2022 Direct
transaction PCVX Common Stock Sale $477,456 -17,052 -29% $28.00 42,187 25 Aug 2022 Direct F1
transaction PCVX Common Stock Options Exercise $6,928 +1,295 +3.1% $5.35 43,482 26 Aug 2022 Direct
transaction PCVX Common Stock Sale $36,260 -1,295 -3% $28.00 42,187 26 Aug 2022 Direct F1
transaction PCVX Common Stock Options Exercise $94,444 +17,653 +42% $5.35 59,840 29 Aug 2022 Direct
transaction PCVX Common Stock Sale $494,284 -17,653 -30% $28.00 42,187 29 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -17,052 -3.5% $0.000000 476,566 25 Aug 2022 Common Stock 17,052 $5.35 Direct F2
transaction PCVX Stock Option (right to buy) Options Exercise $0 -1,295 -0.27% $0.000000 475,271 26 Aug 2022 Common Stock 1,295 $5.35 Direct F2
transaction PCVX Stock Option (right to buy) Options Exercise $0 -17,653 -3.7% $0.000000 457,618 29 Aug 2022 Common Stock 17,653 $5.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.